Navigation Links
OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
Date:8/13/2009

f cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
2. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
3. Cellectar Expands Clinical Management Team
4. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
5. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
6. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... 2014  Mylan Inc. (NASDAQ: MYL ) today ... Abbott (NYSE: ABT ) ... developed markets specialty and branded generics business ("the Assets") in ... will receive 105 million shares of the combined company worth ... on Friday, July 11, 2014, representing an approximately 21% ownership ...
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... component of pharmaceutical marketing and, consequently, organizations are ... specifically for patients. As part of ... learned it,s important to educate, communicate and engage ... from disease awareness to patient empowerment. By mapping ...
(Date:7/11/2014)... Research and Markets  has announced the ... report to their offering. ... a hollow needle commonly used with a syringe to ... fluids from it. A hypodermic needle is used for ... cannot be ingested. Hypodermic needles are broadly classified into ...
Breaking Medicine Technology:Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3
... spine can happen for any number of reasons, whether it,s ... old age, or blunt injury. Unfortunately, people who have experienced ... back braces, reduced mobility, and elongated periods of pain and ... patients are able to restore proper function to the spine ...
... 17, 2011 Zen Holding Corp. (Symbol: ZNHL) today ... name change to Millennium HealthCare Inc.  The Company will ... change as well. About Zen Holding Corp. ... company that operates thru its wholly-owned subsidiaries Greenleaf Management ...
Cached Medicine Technology:Dr. Seyed M. Rezaian's Spinal Fixator a Revolutionary Invention for Healing Injuries of the Thoracolumbar Spine 2Zen Holding Corp. Changes Name to Millennium HealthCare Inc. 2
(Date:7/14/2014)... 14, 2014 EurekaMag.com has newly published ... is a contagious liver disease that ranges in ... to a serious, lifelong illness that attacks the liver. ... have chronic Hepatitis C virus infection of which approximately ... research category covers all studies on Hepatitis C ...
(Date:7/14/2014)... Wa (PRWEB) July 14, 2014 ... Violet Protocol book review recently updated by ... consists of a wide range of simple ... of endometriosis including:, ... meat and dairy products ,     Increasing ...
(Date:7/14/2014)... 2014 Carepoint has been designed ... by combining an intuitive interface for recording, sending, ... service tracking and reporting features. , Hall mc ... teamed up with Rebecca de Witte to create ... organizations. , Carepoint provides seamless, real-time ...
(Date:7/14/2014)... Columbus, OH (PRWEB) July 14, 2014 ... as litigation continues against seven different pelvic mesh manufacturers ... Virginia notes Wright & Schulte LLC. The federal complaints ... Inc. (MDL No. 2327), American Medical Systems (MDL No. ... of June 16th, there are 58,262 Vaginal Mesh lawsuit ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 In ... carriers emphasized lower-cost narrow-network products, accountable care organizations ... chose coverage based on price, rather than on ... from seeking care from out-of-network providers. “Using ... Narrow Networks and Exchange Products,” the July ...
Breaking Medicine News(10 mins):Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Home Health Care Professional and Marketing Firm Team Up to Create New Homecare Communication App 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:Milliman, FAIR Health Executives to Discuss Data-Based Rate Setting for Out-of-Network Providers in Atlantic Information Services Webinar 2
... drug-eluting stents (DES), could be responsible for causing life-threatening// clots ... Centre has warned. ,Angioplasty is a medical ... or blocked blood vessels of the heart. ... vessel is a common procedure, with over 30,000 cases performed ...
... United States, FDA and Centers for Disease Control are trying ... and peanut butter. Around one hundred cases of salmonella infection ... a group of bacteria that is responsible for causing fever, ... and 600 deaths are reported every year. Generally these infections ...
... effect on weakening of muscles and ligaments in women’s body. ... ,According to Dr. Sandler, the levels of hormones oestrogen and ... When the level of oestrogen decreases during the middle of ... and ligaments and women are prone to back pain during ...
... Organization (PAHO) are working with health authorities in Paraguay ... has affected a// number of communities throughout the nation ... America. ,PAHO officials warn that the entire ... prepare for what promises to be a "difficult year" ...
... cells transplanted into rats’ damaged spinal cords have survived, ... own spinal cord cells in a Johns Hopkins laboratory, ... nerve repair. ,A report on the experiments ... and “establishes a new doctrine for regenerative neuroscience,” says ...
... accurate way to predict the risk of developing cardiovascular ... issue of JAMA. ,"In the decade between ... hypertension (high blood pressure), smoking, diabetes and hyperlipidemia (high ... and coined the term coronary risk factors," according to ...
Cached Medicine News:Health News:PAHO Urges Readiness for Dengue Outbreaks in 2007 2Health News:Human Stem Cell Transplants Repair Rat Spinal Cords 2Health News:New Cardiovascular Risk Prediction Models Developed for Women 2
... This microtome is the most convenient ... research and in industrial laboratories. Specimen rise ... setting from 0.5 to 12 microns in ... all MNL Freezing Stages.,Other Associated Products, ...
... The Starter Package is a ... laboratory. The package includes the Vibratome ... blocks, v-block adapter, specimen mounts w/1/2" ... for ease in all of your ...
... is a solid solution for ... package includes the Vibratome Plus, ... blocks, v-block adapter, specimen mounts ... stage assembly for ease in ...
... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
Medicine Products: